Utang jangka cendhak marang modal PDS Biotechnology Corp (PDSB)

The market trend for PDS Biotechnology (PDSB) demonstrates a value of 0.00, which is driven by the use of the Versamune platform to develop oncology drugs. Current price action is supported by expectations regarding the completion of final trials for cervical cancer therapy drugs. Meanwhile, the asset's high resilience is ensured by the specifics of its scientific niche, which remains independent of seasonal fluctuations or economic growth rates.

For PDS Biotechnology (PDSB), which is currently in the stage of costly clinical trials without market revenue, the short-term debt to equity chart reflects the dependence of development rates on short-term borrowing. This metric compares liabilities with a maturity of up to one year against equity, allowing investors to assess liquidity risk and the speed of debt accumulation under conditions of negative operating leverage.